Framing LITESPARK-011 in a Changing RCC Landscape

This opening segment introduces the Between the Lines discussion of the phase 3 LITESPARK-011 study in advanced clear cell renal cell carcinoma (RCC). Drs. Martin Voss and Matthew Campbell outline the program’s focus on interpreting clinical data in the context of real-world decision-making. The conversation begins by framing the evolving RCC treatment landscape, emphasizing how multiple immunotherapy-based combinations have transformed frontline care. The speakers highlight the complexity introduced by these advances, particularly the shift of PD-1–based therapies into earlier lines of treatment, including the adjuvant setting. As a result, clinicians are increasingly managing patients in the immunotherapy-refractory space, where treatment sequencing is less clearly defined. The segment establishes the clinical relevance of evaluating new strategies in this setting and sets up the discussion of LITESPARK-011 as a study designed to address therapeutic gaps after progression on prior PD-(L)1–based therapy.